A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.
대표청구항▼
1. A therapeutic or bioaffecting film delivery system comprising: (a) one or more film matrices comprising at least one polymer;(b) a plurality of nanoparticles incorporated in at least one of said film matrices, said nanoparticles comprising: (i) a core comprising a metal;(ii) a corona comprising a
1. A therapeutic or bioaffecting film delivery system comprising: (a) one or more film matrices comprising at least one polymer;(b) a plurality of nanoparticles incorporated in at least one of said film matrices, said nanoparticles comprising: (i) a core comprising a metal;(ii) a corona comprising a plurality of ligands covalently linked to the core, wherein at least one of said ligands comprises a carbohydrate moiety and at least one of said ligands is a non-carbohydrate ligand comprising an amine group; and(iii) at least one peptide is non-covalently bound to the corona. 2. The film delivery system according to claim 1, wherein the peptide is reversibly bound to the corona. 3. The film delivery system according to claim 1, wherein the peptide is bound to the corona such that at least a fraction of the bound peptide is released from the nanoparticle upon contacting the nanoparticle with a physiological solution. 4. The film delivery system according to claim 3, wherein said release comprises dissociation of bound peptide molecules from the nanoparticle rapidly within minutes followed by further sustained release over a period of at least 2 or more hours. 5. The film delivery system according to claim 3, wherein said release comprises dissociation of bound peptide molecules from the nanoparticle over a period of at least 4 or more hours. 6. The film delivery system according to claim 1, wherein the peptide is capable of stimulating a physiologic response in a mammalian subject. 7. The film delivery system according to claim 1, wherein the peptide is selected from the group consisting of: insulin, GLP-1, IGF1, IGF2, relaxin, INSL5, INSL6, INSL7, pancreatic polypeptide (PP), peptide tyrosine tyrosine (PTT), neuropeptide Y, oxytocin, vasopressin, GnRH, TRH, CRH, GHRH/somatostatin, FSH, LH, TSH, CGA, prolactin, ClIP, ACTH, MSH, enorphins, lipotropin, GH, calcitonin, PTH, inhibin, relaxin, hCG, HPL, glucagons, somatostatin, melatonin, thymosin, thmulin, gastrin, ghrelin, thymopoietin, CCK, GIP secretin, motin VIP, enteroglucagon, IGF-1,IGF-2, leptin, adiponectin, resistin Osteocalcin, renin, EPO, calicitrol, ANP, BNP, chemokines, cytokines, adipokines and biologically active analogs thereof. 8. The film delivery system according to claim 6, wherein the peptide is capable of stimulating a reduction in blood glucose levels in a mammalian subject. 9. The film delivery system according to claim 7, wherein the peptide comprises monomeric and/or dimeric human insulin. 10. The film delivery system according to claim 1, wherein the carbohydrate moiety comprises a monosaccharide and/or a disaccharide. 11. The film delivery system according to claim 10, wherein the carbohydrate moiety comprises a glycoside of galactose, glucose, glucosamine, N-acetylglucosamine, mannose, fucose and/or lactose. 12. The film delivery system according to claim 11, wherein the carbohydrate moiety comprises a galactopyranoside and/or a glucopyranoside. 13. The film delivery system according to claim 1, wherein the carbohydrate moiety is covalently linked to the core via a linker selected from the group consisting of: sulphur-containing linkers, amino-containing linkers, phosphate-containing linkers and oxygen-containing linkers. 14. The film delivery system according to claim 13, wherein the linker comprises an alkyl chain of at least two carbons. 15. The film delivery system according to claim 1, wherein said at least one ligand comprising a carbohydrate moiety is selected from the group consisting of: 2′-thioethyl-α-D-galactopyranoside, 2′-thioethyl-β-D-glucopyranoside, 2′-thioethyl-2-acetamido-2-deoxy-β-D-glucopyranoside, 5′-thiopentanyl-2-deoxy-2-imidazolacetamido-α,β-D-glucopyranoside and 2′-thioethyl-α-D-glucopyranoside, and wherein said at least one ligand comprising a carbohydrate moiety is covalently linked to the core via the thiol sulphur. 16. The film delivery system according to claim 1, wherein said at least one non-carbohydrate ligand comprises 1-amino-17-mercapto-3,6,9,12,15,-pentaoxa-heptadecanol covalently linked to the core via the thiol sulphur. 17. The film delivery system according to claim 1, wherein said at least one ligand comprising a carbohydrate moiety and said at least one non-carbohydrate ligand are different and are present on the nanoparticle in a ratio of 1:40 to 40:1. 18. The film delivery system according to claim 17, wherein in the ratio is 1:10 to 10:1. 19. The film delivery system according to claim 18, wherein the ratio is 1:2 to 2:1. 20. The film delivery system according to claim 1, wherein the corona comprises at least 5 ligands per core. 21. The film delivery system according to claim 20, wherein the corona comprises about 10 to about 1000 ligands per core. 22. The film delivery system according to claim 21, wherein the corona comprises 44-106 ligands per core. 23. The film delivery system according to claim 1, wherein at least 5 or more peptide molecules are bound per core. 24. The film delivery system according to claim 1, wherein the core comprises a metal selected from the group consisting of: Au, Ag, Cu, Pt, Pd, Fe, Co, Gd, Zn or any combination thereof. 25. The film delivery system according to claim 24, wherein the core comprises a passive metal selected from the group consisting of: Au, Ag, Pt, Pd and Cu, or any combination thereof. 26. The film delivery system according to claim 24, wherein the core comprises a combination of metals selected from the group consisting of: Au/Fe, Au/Ag, Au/Cu, Au/Ag/Cu, Au/Pt, Au/Pd, Au/Ag/Cu/Pd, Au/Gd, Au/Fe/Cu, Au/Fe/Gd, Au/Fe/Cu/Gd. 27. The film delivery system according to claim 1, wherein the core is magnetic. 28. The film delivery system according to claim 1, wherein the core further comprises an NMR active atom selected from the group consisting of: Mn2+, Gd3+, Eu2+, Cu2+, V2+, Co2+, Ni2+, Fe2+, Fe3+ and lanthanides3+. 29. The film delivery system according to claim 1, wherein the core further comprises a semiconductor. 30. The film delivery system according to claim 29, wherein the semiconductor is selected from the group consisting of: cadmium selenide, cadmium sulphide, cadmium tellurium and zinc sulphide. 31. The film delivery system according to claim 1, wherein the core comprises a metal oxide coated with a metal selected from the group consisting of: Au, Ag, Cu, Pt, Pd and Zn, or any combination thereof. 32. The film delivery system according to claim 31, wherein said metal oxide is of the formula XFe2O4, where X is a metal selected from the group consisting of: Fe, Mn and Co. 33. The film delivery system according to claim 1, wherein the nanoparticle cores have an average diameter in the range of about 0.5 nm to about 50 nm. 34. The film delivery system according to claim 33, wherein said average diameter is in the range of about 1 nm to about 10 nm. 35. The film delivery system according to claim 33, wherein said average diameter is in the range of about 1.5 nm to about 2 nm. 36. The film delivery system according to claim 1, wherein the nanoparticle core comprises a divalent component. 37. The film delivery system according to claim 36, wherein said divalent component is present in the corona of the nanoparticle. 38. The film delivery system according to claim 36, wherein said divalent component is selected from the group consisting of divalent metals, divalent metal compounds or other components having a divalent state. 39. The film delivery system according to claim 36, wherein said divalent component is selected from the group consisting of zinc, magnesium, copper, nickel, cobalt, cadmium, or calcium, their oxides and salts thereof. 40. The film delivery system according to claim 39, wherein said zinc is selected from: Zn2+ and ZnO. 41. The film delivery system according to claim 40, wherein the zinc comprises ZnCl2. 42. The film delivery system according to claim 36, wherein said divalent component is present in an amount sufficient to produce a stabilizing effect. 43. The film delivery system according to claim 42, wherein said divalent component is present in an amount of about 0.5 to about 2.0 equivalents of said metal in said core. 44. The film delivery system according to claim 42, wherein said divalent component is present in an amount of about 0.75 to about 1.5 equivalents of said metal in said core. 45. The film delivery system according to claim 1, wherein the one or more film matrices are formed by evaporating a solvent carrier from the matrices to form a visco-elastic film within about the first 10 minutes of applying heat or radiation energy whereby the nanoparticles are locked in or substantially prevented from migrating within the matrices to provide a film delivery system with a uniform distribution of the nanoparticles. 46. The film delivery system according to claim 45, divided into individual dosage units, each dosage unit having an appropriate amount of peptide for administration, wherein said uniform distribution of the nanoparticles is such that the amount of peptide in each dosage unit does not vary more than 10% from said appropriate amount. 47. The film delivery system according to claim 1, wherein the one or more film matrices comprise two film layers having different release properties. 48. The film delivery system according to claim 1, wherein the one or more film matrices comprise at least one water soluble or water swellable polymer. 49. The film delivery system according to claim 48, wherein the at least one water soluble or water swellable polymer is selected from the group consisting of polyethylene oxide, cellulose, a cellulose derivative, pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, carboxyvinyl copolymers, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium alginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, and combinations thereof, alone or in combination with polyethylene oxide. 50. The film delivery system of claim 49, wherein said polymer further comprises a polymer selected from the group consisting of sodium alginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, starch, gelatin, carageenan, locust bean gum, dextran, gellan gum, pullulan and combinations thereof. 51. The film delivery system of claim 49, wherein said polymer further comprises a polymer selected from the group consisting of ethylcellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinylacetatephthalates, phthalated gelatin, crosslinked gelatin, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polycaprolactone, methylmethacrylate copolymer, polyacrylic acid polymer, poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polydioxanoes, polyoxalates, poly ({acute over (α)}-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acides, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly(alkyl cyanoacrylates), sodium alginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, starch, gelatin, carageenan, locust bean gum, dextran, gellan gum and combinations thereof. 52. The film delivery system of claim 49, wherein said solvent is selected from the group consisting of water, polar organic solvent, and combinations thereof. 53. The film delivery system of claim 48, wherein the at least one water soluble or water swellable polymer is selected from the group consisting of ethylcellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinylacetatephthalates, phthalated gelatin, crosslinked gelatin, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polycaprolactone and combinations thereof. 54. The film delivery system of claim 48, wherein the at least one water soluble or water swellable polymer is selected from the group consisting selected from the group consisting of methylmethacrylate copolymer, polyacrylic acid polymer, poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polydioxanoes, polyoxalates, poly ({acute over (α)}-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acides, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly(alkyl cyanoacrylates), and mixtures and copolymers thereof. 55. The film delivery system according to claim 1, wherein the nanoparticles are uniformly distributed within the at least one or more film matrices. 56. The film delivery system according to claim 1, where in the total water content is about 10% or less by weight of the delivery system. 57. The film delivery system according to claim 1, wherein the nanoparticles are incorporated or deposited on the surface of the one or more film matrices. 58. The film delivery system according to claim 1, further comprising a permeation and/or penetration enhancing agent. 59. The film delivery system of claim 58, wherein the permeation or penetration enhancing agent is selected from the group consisting of medium chain mono and diacylglycerol fatty acid derivatives, synthetic and natural surfactants, medium chain fatty acids and salts and esters thereof, bile salts, chelating agents, detergents, phospholipids, lecithins, cetomacrogels, glycerol and polyalkylene glycols and their esters, salicylates, polysorbates, alkylsulfoxides, alkanols, fatty acids and their corresponding esters and alcohols, urea and cyclic ureas, pyrrolidone derivatives, alkyl and cyclic amides, anionic surfactants, cationic surfactants, non-ionic surfactants, ketones, alkyl oxides, cycloalkene oxides, oils, alkyl glycosides, zonula occuludens, alcohols, and combinations thereof. 60. The film delivery system according to claim 58, wherein the permeation enhancing agent is coupled to the nanoparticle core and/or the nanoparticle corona. 61. The film delivery system according to claim 1, divided into individual dosage units, each dosage unit having an appropriate amount of peptide for administration, wherein the amount of peptide in each dosage unit does not vary more than 10% from said appropriate amount. 62. An insulin-containing film delivery system comprising: (a) one or more film matrices comprising at least one polymer;(b) a plurality of nanoparticles incorporated in at least one of said film matrices, said nanoparticles comprising: (i) a core comprising a gold;(ii) a plurality of ligands covalently attached to the core and forming a corona around the core, wherein the ligands comprise 2″-thioethyl-α-D-galactopyranoside and 1-amino-17-mercapto-3,6,9,12,15,-pentaoxa-heptadecanol each bonded to the core via their respective sulphur atoms, and wherein the nanoparticles have an average of at least five insulin monomers non-covalently bound to the corona per nanoparticle core. 63. A therapeutic or bioaffecting film delivery system comprising: (a) one or more film matrices comprising at least one polymer;(b) a plurality of nanoparticles incorporated in at least one of said film matrices, said nanoparticles comprising: (i) a core comprising a metal;(ii) a corona comprising a plurality of ligands covalently linked to the core, wherein at least one of said ligands comprises a carbohydrate moiety and at least one of said ligands is a non-carbohydrate ligand; and(iii) at least one peptide is non-covalently bound to the corona, wherein said at least one ligand comprising a carbohydrate moiety and said at least one non-carbohydrate ligand are present on the nanoparticle in a ratio of 1:40 to 40:1. 64. The film delivery system according to claim 63, wherein the peptide is reversibly bound to the corona. 65. The film delivery system according to claim 63, wherein the peptide is bound to the corona such that at least a fraction of the bound peptide is released from the nanoparticle upon contacting the nanoparticle with a physiological solution. 66. The film delivery system according to claim 65, wherein said release comprises dissociation of bound peptide molecules from the nanoparticle rapidly within minutes followed by further sustained release over a period of at least 2 or more hours. 67. The film delivery system according to claim 65, wherein said release comprises dissociation of bound peptide molecules from the nanoparticle over a period of at least 4 or more hours. 68. The film delivery system according to claim 63, wherein the peptide is capable of stimulating a physiologic response in a mammalian subject. 69. The film delivery system according to claim 68, wherein the peptide is capable of stimulating a reduction in blood glucose levels in a mammalian subject. 70. The film delivery system according to claim 63, wherein the peptide is selected from the group consisting of: insulin, GLP-1, IGF1, IGF2, relaxin, INSL5, INSL6, INSL7, pancreatic polypeptide (PP), peptide tyrosine tyrosine (PTT), neuropeptide Y, oxytocin, vasopressin, GnRH, TRH, CRH, GHRH/somatostatin, FSH, LH, TSH, CGA, prolactin, ClIP, ACTH, MSH, enorphins, lipotropin, GH, calcitonin, PTH, inhibin, relaxin, hCG, HPL, glucagons, somatostatin, melatonin, thymosin, thmulin, gastrin, ghrelin, thymopoietin, CCK, GIP secretin, motin VIP, enteroglucagon, IGF-1,IGF-2, leptin, adiponectin, resistin Osteocalcin, renin, EPO, calicitrol, ANP, BNP, chemokines, cytokines, adipokines and biologically active analogs thereof. 71. The film delivery system according to claim 70, wherein the peptide comprises monomeric and/or dimeric human insulin. 72. The film delivery system according to claim 63, wherein the carbohydrate moiety comprises a monosaccharide and/or a disaccharide. 73. The film delivery system according to claim 72, wherein the carbohydrate moiety comprises a glycoside of galactose, glucose, glucosamine, N-acetylglucosamine, mannose, fucose and/or lactose. 74. The film delivery system according to claim 72, wherein the carbohydrate moiety comprises a galactopyranoside and/or a glucopyranoside. 75. The film delivery system according to claim 63, wherein the carbohydrate moiety is covalently linked to the core via a linker selected from the group consisting of: sulphur-containing linkers, amino-containing linkers, phosphate-containing linkers and oxygen-containing linkers. 76. The film delivery system according to claim 75, wherein the linker comprises an alkyl chain of at least two carbons. 77. The film delivery system according to claim 63, wherein said at least one ligand comprising a carbohydrate moiety is selected from the group consisting of: 2″-thioethyl-α-D-galactopyranoside, 2′-thioethyl-β-D-glucopyranoside, 2′-thioethyl-2-acetamido-2-deoxy-β-D-glucopyranoside, 5′-thiopentanyl-2-deoxy-2-imidazolacetamido-α,β-D-glucopyranoside and 2′-thioethyl-α-D-glucopyranoside, and wherein said at least one ligand comprising a carbohydrate moiety is covalently linked to the core via the thiol sulphur. 78. The film delivery system according to claim 63, wherein said at least one non-carbohydrate ligand comprises an amine group. 79. The film delivery system according to claim 78, wherein said at least one non-carbohydrate ligand comprises 1-amino-17-mercapto-3,6,9,12,15,-pentaoxa-heptadecanol covalently linked to the core via the thiol sulphur. 80. The film delivery system according to claim 63, wherein in the ratio is 1:10 to 10:1. 81. The film delivery system according to claim 63, wherein the ratio is 1:2 to 2:1. 82. The film delivery system according to claim 63, wherein the corona comprises at least 5 ligands per core. 83. The film delivery system according to claim 82, wherein the corona comprises about 10 to about 1000 ligands per core. 84. The film delivery system according to claim 82, wherein the corona comprises 44-106 ligands per core. 85. The film delivery system according to claim 63, wherein at least 5 or more peptide molecules are bound per core. 86. The film delivery system according to claim 63, wherein the core comprises a metal selected from the group consisting of: Au, Ag, Cu, Pt, Pd, Fe, Co, Gd, Zn or any combination thereof. 87. The film delivery system according to claim 86, wherein the core comprises a passive metal selected from the group consisting of: Au, Ag, Pt, Pd and Cu, or any combination thereof. 88. The film delivery system according to claim 86, wherein the core comprises a combination of metals selected from the group consisting of: Au/Fe, Au/Ag, Au/Cu, Au/Ag/Cu, Au/Pt, Au/Pd, Au/Ag/Cu/Pd, Au/Gd, Au/Fe/Cu, Au/Fe/Gd, Au/Fe/Cu/Gd. 89. The film delivery system according to claim 63, wherein the core is magnetic. 90. The film delivery system according to claim 63, wherein the core further comprises an NMR active atom selected from the group consisting of: Mn2+, Gd3+, Eu2+, Cu2+, V2+, Co2+, Ni2+, Fe2+, Fe3+ and lanthanides3+. 91. The film delivery system according to claim 63, wherein the core further comprises a semiconductor. 92. The film delivery system according to claim 91, wherein the semiconductor is selected from the group consisting of: cadmium selenide, cadmium sulphide, cadmium tellurium and zinc sulphide. 93. The film delivery system according to claim 63, wherein the core comprises a metal oxide coated with a metal selected from the group consisting of: Au, Ag, Cu, Pt, Pd and Zn, or any combination thereof. 94. The film delivery system according to claim 93, wherein said metal oxide is of the formula XFe2O4, where X is a metal selected from the group consisting of: Fe, Mn and Co. 95. The film delivery system according to claim 63, wherein the nanoparticle cores have an average diameter in the range of about 0.5 nm to about 50 nm. 96. The film delivery system according to claim 95, wherein said average diameter is in the range of about 1 nm to about 10 nm. 97. The film delivery system according to claim 95, wherein said average diameter is in the range of about 1.5 nm to about 2 nm. 98. The film delivery system according to claim 63, wherein the nanoparticle core comprises a divalent component. 99. The film delivery system according to claim 98, wherein said divalent component is present in the corona of the nanoparticle. 100. The film delivery system according to claim 98, wherein said divalent component is selected from the group consisting of divalent metals, divalent metal compounds or other components having a divalent state. 101. The film delivery system according to claim 98, wherein said divalent component is selected from the group consisting of zinc, magnesium, copper, nickel, cobalt, cadmium, or calcium, their oxides and salts thereof. 102. The film delivery system according to claim 101, wherein said zinc is selected from: Zn2+ and ZnO. 103. The film delivery system according to claim 102, wherein the zinc comprises ZnCl2. 104. The film delivery system according to claim 98, wherein said divalent component is present in an amount sufficient to produce a stabilizing effect. 105. The film delivery system according to claim 104, wherein said divalent component is present in an amount of about 0.5 to about 2.0 equivalents of said metal in said core. 106. The film delivery system according to claim 104, wherein said divalent component is present in an amount of about 0.75 to about 1.5 equivalents of said metal in said core. 107. The film delivery system according to claim 63, wherein the one or more film matrices are formed by evaporating a solvent carrier from the matrices to form a visco-elastic film within about the first 10 minutes of applying heat or radiation energy whereby the nanoparticles are locked in or substantially prevented from migrating within the matrices to provide a film delivery system with a uniform distribution of the nanoparticles. 108. The film delivery system according to claim 107, divided into individual dosage units, each dosage unit having an appropriate amount of peptide for administration, wherein said uniform distribution of the nanoparticles is such that the amount of peptide in each dosage unit does not vary more than 10% from said appropriate amount. 109. The film delivery system according to claim 63, wherein the one or more film matrices comprise two film layers having different release properties. 110. The film delivery system according to claim 63, wherein the one or more film matrices comprise at least one water soluble or water swellable polymer. 111. The film delivery system according to claim 110, wherein the at least one water soluble or water swellable polymer is selected from the group consisting of polyethylene oxide, cellulose, a cellulose derivative, pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, carboxyvinyl copolymers, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium alginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, and combinations thereof, alone or in combination with polyethylene oxide. 112. The film delivery system of claim 111, wherein said polymer further comprises a polymer selected from the group consisting of sodium alginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, starch, gelatin, carageenan, locust bean gum, dextran, gellan gum, pullulan and combinations thereof. 113. The film delivery system of claim 111, wherein said polymer further comprises a polymer selected from the group consisting of ethylcellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinylacetatephthalates, phthalated gelatin, crosslinked gelatin, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polycaprolactone, methylmethacrylate copolymer, polyacrylic acid polymer, poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polydioxanoes, polyoxalates, poly ({acute over (α)}-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acides, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly(alkyl cyanoacrylates), sodium alginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, starch, gelatin, carageenan, locust bean gum, dextran, gellan gum and combinations thereof. 114. The film delivery system of claim 111, wherein said solvent is selected from the group consisting of water, polar organic solvent, and combinations thereof. 115. The film delivery system of claim 110, wherein the at least one water soluble or water swellable polymer is selected from the group consisting of ethylcellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinylacetatephthalates, phthalated gelatin, crosslinked gelatin, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polycaprolactone and combinations thereof. 116. The film delivery system of claim 110, wherein the at least one water soluble or water swellable polymer is selected from the group consisting selected from the group consisting of methylmethacrylate copolymer, polyacrylic acid polymer, poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, polydioxanoes, polyoxalates, poly ({acute over (α)}-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acides, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly(alkyl cyanoacrylates), and mixtures and copolymers thereof. 117. The film delivery system according to claim 63, wherein the nanoparticles are uniformly distributed within the at least one or more film matrices. 118. The film delivery system according to claim 63, where in the total water content is about 10% or less by weight of the delivery system. 119. The film delivery system according to claim 63, wherein the nanoparticles are incorporated or deposited on the surface of the one or more film matrices. 120. The film delivery system according to claim 63, further comprising a permeation and/or penetration enhancing agent. 121. The film delivery system of claim 120, wherein the permeation or penetration enhancing agent is selected from the group consisting of medium chain mono and diacylglycerol fatty acid derivatives, synthetic and natural surfactants, medium chain fatty acids and salts and esters thereof, bile salts, chelating agents, detergents, phospholipids, lecithins, cetomacrogels, glycerol and polyalkylene glycols and their esters, salicylates, polysorbates, alkylsulfoxides, alkanols, fatty acids and their corresponding esters and alcohols, urea and cyclic ureas, pyrrolidone derivatives, alkyl and cyclic amides, anionic surfactants, cationic surfactants, non-ionic surfactants, ketones, alkyl oxides, cycloalkene oxides, oils, alkyl glycosides, zonula occuludens, alcohols, and combinations thereof. 122. The film delivery system according to claim 120, wherein the permeation enhancing agent is coupled to the nanoparticle core and/or the nanoparticle corona. 123. The film delivery system according to claim 63, divided into individual dosage units, each dosage unit having an appropriate amount of peptide for administration, wherein the amount of peptide in each dosage unit does not vary more than 10% from said appropriate amount.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (121)
Altwirth Oskar (Oberach 37 A-4950 Altheim ATX), Adherent insert for artificial teeth and process of manufacturing the insert.
Babaian Eduard A. (Moscow SUX) Gerasimova Galina A. (Moscow SUX) Davydov Anatoly B. (Moscow SUX) Utyamyshev Rustam I. (Moscow SUX) Khromov Gennady L. (Moscow SUX) Metelitsa Vladimir I. (Moscow SUX) V, Antianginal film and method of treating ischemic heart disease.
Hijiya Hiromi (Okayama JPX) Miyake Toshio (Okayama JPX), Association complex comprising pullulan and polyethylene glycol, and preparation and uses of the same.
Rel Bernhard (Knigstein/Taunus DEX) Petri Walter (Niedernhausen/Taunus DEX), Base for mucosal and denture adhesive pastes, a process for the preparation thereof, and pastes having this base.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Michael A. Repka ; Staci L. Repka ; James W. McGinity, Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof.
Norton Richard L. (Fort Collins CO) Knight Stephen Michael Gregory (Fort Collins CO) Tipton Arthur J. (Birmingham AL), Biodegradable polymeric composition.
Fischel-Ghodsian Fariba (2122 Century Park La. ; #104 Los Angeles CA 90067), Device for controlled release of vaporous medications through nasal route.
Hymes Alan C. (Minnetonka MN) Ong Lincoln T. (Minnetonka MN) Persons Garry R. (Edina MN), Drug dispensing device for transdermal delivery of medicaments.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Jevne Allan H. (Anoka MN) Vegoe Brett R. (Brooklyn Park MN) Holmblad Carolann M. (Cambridge MN) Cahalan Patrick T. (Champlin MN), Hydrophilic pressure sensitive biomedical adhesive composition.
Broberg Berndt F. J. (Sdertlje SEX) Evers Hans C. A. (Sdertlje SEX), Local anesthetic mixture for topical application and method for obtaining local anesthesia.
Leusner Bernd (Leverkusen DEX) Heiss Rdiger (Grefrath DEX) Pelster Bernd (St. Augustin DEX) Fischer Wolfgang (Bergisch Gladbach DEX) Ohm Ulrich (Odenthal DEX), Medicaments for the region of the oral cavity.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Kizawa Hidenori (Tokyo JPX) Fujiyama Norimasa (Tokyo JPX) Kobayashi Jitsuo (Kanagawa JPX) Ito Akinori (Niigata JPX), Mucous membrane-adhering film preparation and process for its preparation.
Sorrentino James V. (Wilton CT) Kelleher William J. (Storrs CT) Moye Jeanne O. (Fairfield CT), Pharmaceutical compositions containing dyclonine HC1 and phenol.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Noguchi Toshihide (Tokyo JPX) Izumizawa Katsunori (Yokohama JPX) Kinoshita ; deceased Shiro (late of Tokyo JPX by Kimiko Kinoshita ; Atsuhiro Kinosh, Pharmaceutical preparation for remedy of periodontal disease and process for production thereof.
Vert Michel (Mont-Saint-Aignan FRX) Mauduit Jacques (Bacqueville En Caux FRX) Bukh Niels (Hellerup DKX), Polylactic acid-based implant susceptible of bioresorption containing and antibiotic.
Schmidt Wolfgang (Reembroden 44 D-2000 Hamburg 63 DEX), Process for producing an administration or dosage form for drugs, reagents or other active ingredients.
Horstmann Michael (Neuwied DEX) Laux Wolfgang (Dietz DEX) Hungerbach Stefan (Nortershausen DEX), Rapidly disintegrating sheet-like presentations of multiple dosage units.
Chang Yunik (Lakewood NJ) Patel Dinesh C. (Murray UT), Skin penetration enhancement using free base and acid addition salt combinations of active agents.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Wheatley Margaret A. (Arlington MA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for delayed and pulsed release of biologically active substances.
AF Ekenstam Bo T. (Box 721 Hjlteby SEX S-440 74) Aberg Gunnar A. K. (Utsiktsvgen 7 Falkenberg SEX S-311 00), Therapeutically active, substituted piperidines and pyrrolidines therapeutic compositions thereof and methods of use the.
Heiber Sonia J. (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT) Dave Sirish C. (Salt Lake City UT), Transmucosal delivery of macromolecular drugs.
Biegajski James E. (Foster City CA) Venkatraman Subbu S. (Palo Alto CA) Scott Ann M. (Mountain View CA), Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavi.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.